Join
Live feed
·
PRReleasevia Quantisnow
Hepion Pharmaceuticals Inc. logo

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

ByQuantisnow·Wall Street's wire, on your screen.
HEPA· Hepion Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HEPA (Hepion Pharmaceuticals Inc.) and more on Quantisnow.